JP2023532217A5 - - Google Patents
Info
- Publication number
- JP2023532217A5 JP2023532217A5 JP2022577746A JP2022577746A JP2023532217A5 JP 2023532217 A5 JP2023532217 A5 JP 2023532217A5 JP 2022577746 A JP2022577746 A JP 2022577746A JP 2022577746 A JP2022577746 A JP 2022577746A JP 2023532217 A5 JP2023532217 A5 JP 2023532217A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- crystal form
- cancer
- ray powder
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020096778 | 2020-06-18 | ||
| CNPCT/CN2020/096778 | 2020-06-18 | ||
| PCT/CN2021/100673 WO2021254449A1 (zh) | 2020-06-18 | 2021-06-17 | 一种shp2抑制剂的晶型及其组合物、制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023532217A JP2023532217A (ja) | 2023-07-27 |
| JP2023532217A5 true JP2023532217A5 (cg-RX-API-DMAC7.html) | 2024-06-25 |
Family
ID=79268476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022577746A Pending JP2023532217A (ja) | 2020-06-18 | 2021-06-17 | Ｓｈｐ２阻害剤の結晶形、その組成物、その製造方法及び応用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230339975A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4169920A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023532217A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230026458A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115698007A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021290733A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3183063A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021254449A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3860717A1 (en) * | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| CN117143079A (zh) * | 2018-11-06 | 2023-12-01 | 上海奕拓医药科技有限责任公司 | 一种螺芳环化合物及其应用 |
| JP2022506887A (ja) * | 2018-11-07 | 2022-01-17 | シャンハイ リンジーン バイオファーマ カンパニー リミテッド | 窒素含有縮合複素環系ｓｈｐ２阻害剤化合物、製造方法及び使用 |
| EP3889153A4 (en) * | 2018-11-30 | 2022-09-07 | Tuojie Biotech (Shanghai) Co., Ltd. | PYRIMIDINE AND FIVE-MEMBERED HETEROCYCLIC NITROGEN DERIVATIVE, METHOD OF MANUFACTURE THEREOF AND MEDICAL USES THEREOF |
| US20220073521A1 (en) * | 2018-11-30 | 2022-03-10 | Tuojie Biotech (Shanghai) Co., Ltd. | Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof |
| KR20220054285A (ko) * | 2019-06-28 | 2022-05-02 | 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 | 피리미딘 5 원 질소 헤테로고리형 유도체, 이의 제조 방법 및 이의 약학적 용도 |
| WO2021088945A1 (zh) * | 2019-11-08 | 2021-05-14 | 南京圣和药业股份有限公司 | 作为shp2抑制剂的化合物及其应用 |
| CN113754683A (zh) * | 2020-06-05 | 2021-12-07 | 上海奕拓医药科技有限责任公司 | 同位素取代的螺芳环化合物及其应用 |
-
2021
- 2021-06-17 US US18/002,196 patent/US20230339975A1/en active Pending
- 2021-06-17 WO PCT/CN2021/100673 patent/WO2021254449A1/zh not_active Ceased
- 2021-06-17 CN CN202180043362.7A patent/CN115698007A/zh active Pending
- 2021-06-17 JP JP2022577746A patent/JP2023532217A/ja active Pending
- 2021-06-17 EP EP21826764.9A patent/EP4169920A4/en not_active Withdrawn
- 2021-06-17 CA CA3183063A patent/CA3183063A1/en active Pending
- 2021-06-17 AU AU2021290733A patent/AU2021290733A1/en not_active Abandoned
- 2021-06-17 KR KR1020237002092A patent/KR20230026458A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110292580B (zh) | 用于制备抗癌剂al3818、其结晶形式和其盐的方法 | |
| CA2868081C (en) | Inhibition of mcl-1 and/or bfl-1/a1 | |
| CN111051300B (zh) | 作为组蛋白脱乙酰基酶1和/或2(hdac1-2)的选择性抑制剂的新杂芳基酰胺衍生物 | |
| RU2014151565A (ru) | Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида | |
| EP2868660B1 (en) | Antitumor effect potentiator comprising an imidazooxazine compound | |
| JP2017537946A5 (cg-RX-API-DMAC7.html) | ||
| JP2016513704A5 (cg-RX-API-DMAC7.html) | ||
| WO2017152706A1 (zh) | 吡啶胺基嘧啶衍生物的盐及其制备方法和应用 | |
| CN109111426A (zh) | 一类稠合双环杂芳基或芳基化合物，及其用途 | |
| JP2019507776A (ja) | ピリジニルアミノピリミジン誘導体のメシル酸塩の結晶形、その製造方法及びその使用 | |
| RU2014142057A (ru) | Комплексная терапия | |
| WO2022083657A1 (zh) | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 | |
| JP2019501185A (ja) | 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット | |
| JP2019529475A5 (cg-RX-API-DMAC7.html) | ||
| JP2016537326A5 (cg-RX-API-DMAC7.html) | ||
| EP4077314A1 (en) | Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer | |
| JP2022515239A5 (cg-RX-API-DMAC7.html) | ||
| JP2023532217A5 (cg-RX-API-DMAC7.html) | ||
| US20150374646A1 (en) | Treatment of cancer and other conditions using a transcription factor modulator | |
| TW202246254A (zh) | 聯芳組成物和調控激酶級聯之方法 | |
| TWI374880B (en) | A pharmaceutically acceptable salt and solvate of n-[3-[[[2-[(2,3-dihydro-2-oxo-1h-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-2-pyridinyl]-n-methylmethanesulfonamide and uses thereof | |
| CN103923081B (zh) | 化合物及其制备方法和应用 | |
| CN103626761B (zh) | 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用 | |
| CN105985321B (zh) | 吡唑酞嗪化合物及其制备方法和用途 | |
| JP2013510899A5 (cg-RX-API-DMAC7.html) |